Diabetes
Conference Coverage
Experts express caution over
type 2 diabetes/tea-drinking claim
Drinking four cups of tea a day was linked to a 17% lower risk for developing type 2 diabetes in a study, but experts warn these data are...
Conference Coverage
At EASD, docs to eye new tactics for type 2 diabetes
New data on tirzepatide for weight loss and potential type 2 diabetes remission as well as an update on use of dapagliflozin for heart failure...
Latest News
Your poop may hold the secret to long life
If we could pull off a banking system like this, it could have the potential to treat autoimmune disease, inflammatory bowel disease, diabetes,...
From the Journals
Lack of exercise linked to small heart, HFpEF
Chronic “exercise deficiency” is a major risk factor for heart failure with preserved ejection fraction, and regular physical activity ... may...
Feature
New AI tech could detect type 2 diabetes without a blood test
An algorithm that predicts diabetes risk on the basis of noninvasive heart measurements could be developed into a user-friendly at-home test.
Conference Coverage
Evolocumab benefits accrue with longer follow-up: FOURIER OLE
Chief among the benefits was a reduction in cardiovascular mortality not observed in the pivotal trial that led to U.S. approval of evolocumab.
Feature
How do you live with COVID? One doctor’s personal experience
Early in 2020, Anne Peters, MD, caught COVID-19. The author of Medscape’s “Peters on Diabetes” column was sick in March 2020 before state-mandated...
Conference Coverage
Albuminuria linked to higher CVD risk in diabetes
An analysis of more than 74,000 Danish people with type 2 diabetes showed an elevated CVD event rate in those with albuminuria.
Conference Coverage
DANCAVAS misses primary endpoint but hints at benefit from comprehensive CV screening
Comprehensive cardiovascular screening fell short of significantly reducing all-cause mortality in men aged 65-74, but some benefits were seen.
Conference Coverage
Dapagliflozin’s HFpEF benefit recasts heart failure treatment: DELIVER
Results from DELIVER made dapagliflozin the third SGLT2 inhibitor to benefit patients with HFpEF, cementing a new, ejection fraction–agnostic...
Conference Coverage
Secondary CV prevention benefit from polypill promises global health benefit
In older patients with a prior myocardial infarction, a three-drug polypill significantly reduced risk of CV events in the multinational SECURE...